Hormone Refractory Prostate Cancer Disease
1 clinical trials · Condition
◉ Watch Hormone Refractory Prostate Cancer Disease
| Record | Firm | Date |
|---|---|---|
| Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone (NCT00419536) | Novartis Pharmaceuticals | 2006-05-01 |
Track Hormone Refractory Prostate Cancer Disease automatically
Every clearance here is in the API, with alerts when new ones post.